Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma Progressing on Platinum-based Chemotherapy and PD1/L1 Inhibitors: the Double Antibody Drug Conjugate (DAD) Phase I Trial
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2024 Trial amended to include 2 cohorts of distinct patient populations; one expanding SG+EV (DAD) and a second exploring the SG+EV+P (DAD-IO) combination. DAD-IO cohort, will be in patients with treatment naive metastatic urothelial carcinoma. Primary endpoint ORR added newly.
- 04 Jun 2024 Study design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 07 May 2024 According to a Gilead Sciences media release, data from this trial to be presented in abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.